All In Biotech

NDA 021430 · Celgene

Thalomid

Thalidomide · Oral

Accelerated approvalOrphan

Last checked: Nov 20, 2026Latest source record: May 25, 2006 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2006

May 25, 2006

Approved uses

1

Original approval plus efficacy supplements

Registered trials

431

94 Phase 3, 25 recruiting

FAERS reports

36,691

32,479 serious, 12,186 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • THALOMID · THALIDOMIDE 200MG · CAPSULE, ORAL · Prescription
  • THALOMID · THALIDOMIDE 50MG · CAPSULE, ORAL · Prescription
  • THALOMID · THALIDOMIDE 100MG · CAPSULE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Thalidomide" as an intervention, any sponsor and status, largest first.

All 431 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death6,421
  • disease progression2,495
  • plasma cell myeloma2,058
  • off label use1,842
  • neuropathy peripheral1,829
  • pneumonia1,716
  • fatigue1,418
  • drug ineffective1,169
  • anaemia1,026
  • asthenia1,024
  • constipation1,001
  • dyspnoea995

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20044,416
20054,279
2006809
2007769
20082,021
2009983
2010900
2011951
2012956
20131,128
20141,621
20152,888
20161,716
20171,464
20181,456
20191,520
20201,487
20211,447
20221,635
20231,454
20241,182
20251,009
2026600

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Thalomid (Thalidomide)

2024 spending

$19.8M

Beneficiaries

473

2,683 claims

Per beneficiary

$41,762

$225.16 per unit

View as table
YearSpending
2020$33,138,478
2021$28,865,933
2022$24,535,859
2023$19,395,778
2024$19,753,380

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,068 on PubMed

Sponsor: Bristol Myers Squibb

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.